Partnering with Taiwan's top-notch institute that accelerates commercialisation of new drugs!
DCB has developed four- plasmids-based lentivirus vectors (LV). These plasmids have been optimized to produce relative high titers and high infectivity virus. For the preparation of high-quality LV DNA plasmids, the methods including manufacturing, purification and characterization are established based on the regulatory requirement.
